CX1739

Phase 2Small molecule

RRespireRx

CX1739 is one of 16 small molecule programs targeting Respiratory Depression. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory DepressionActive, not recruiting

Respiratory DepressionPhase 2

Active, not recruiting

Competition

Competitive Landscape

26 competitors in Respiratory Depression

#DrugCompanyPhaseTrials

Narcan

SScienture

Approved

2 2

Anerem

AAcacia Pharma Ltd

Approved

1 3

Duragesic

CCephalon

Approved

1 4

MS Contin

HHikma Pharmaceuticals LLC

Tylenol

1 6

Selincro

IIndivior Inc.

Phase 3

1 7

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 2

1 8

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 1

3 9

Fentanyl, Dexmedetomidine

UUniversity of Saskatchewan

Phase 3

1 10

Acetaminophen, Gabapentin

UUniversity of Saskatchewan

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Respiratory Depression1 trial

Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia

Unknown status·RRespireRx·Phase 2·NCT02735629·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CX1739. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CX1739 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CX1739. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — RespireRx company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RRespireRx

CX1739

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Respiratory Depression1 trial

References

Drug Info

Quick Facts

Related News